16-JUN-2024 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo 1 Y 1 Encorafenib/Binimetinib/Nivolu 35 19 6 5 3 3 0 01/06/2021 112 45
        2 Ipilimumab + Nivolumab   18 3 3 2 1 0      
            37 9 8 5 4 0      
 
Yes EA6141-Melan, Adv, Nivolumab+Ipi ± Sargmostim 1 E Total Registrations   61 9 4 2 0 0 03/25/2016 240 94
            61 9 4 2 0 0      
 
  EA6194-Melan, Stage IIIB-D, Pembro +/- CMP-001 1 E Total Registrations   4 4 4 0 0 0 12/22/2023 1 3
            4 4 4 0 0 0      
 
No S2015-MELAN, Stg I-II, 1cm v 2cm excision margins 1 E Total Registrations   662 432 205 119 49 6 05/12/2022 157 65
            662 432 205 119 49 6      
 
  A091903-Melan, Resected Mucosal, Adj Nivo +/- Cabo 0 E Total Registrations   1 0 0 0 0 0 11/01/2022 94 52
            1 0 0 0 0 0      
 
    1 E Total Registrations   1 0 0 0 0 0 11/01/2022    
            1 0 0 0 0 0      
 
  EA6174-Merkel, Adjuvant Pembrolizumab vs Observation 1 E Total Registrations   53 0 0 0 0 0 05/01/2019 306 104
            53 0 0 0 0 0      
 
  EA6192-Melan, Adv, Erly Discont of Antibdy Thrpy 0 E Total Registrations   8 1 1 1 1 0 09/22/2021 114 49
            8 1 1 1 1 0      
 
    1 E Total Registrations   9 1 1 1 1 1 09/22/2021    
            9 1 1 1 1 1